Targeting the Granuloma: Tumor necrosis-alpha inhibitors for sarcoidosis & Imaging Considerations in Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Acute vs Chronic (Part 1)
Program Release: January 19, 2021
Expiration Date: June 19, 2021
Estimated time to complete: 60 Minutes
There are no prerequisites for participation.
Barry Shea, MD
Assistant Professor of Medicine
Christopher Theroux, MD
Pulmonary and Critical Care Fellow
Physicians, Physician Assistants, Residents & Fellows.
- Identify the role that tumor necrosis factor (TNF) alpha plays in the pathogenesis of sarcoidosis
- Summarize the data supporting the use of TNF-alpha inhibitors for refractory sarcoidosis
- Recognize the need for further research into treatment options for refractory sarcoidosis
- Review the definition, incidence, and pathophysiology of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
- Outline the diagnostic algorithm in the diagnosis of CTEPH
- Compare CTA image findings associated with acute vs. chronic pulmonary emboli
Method of Participation and How to Receive CME Credit
There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives, faculty information, and CME information prior to participating in the activity.
- View the CME presentations
- Complete the CME activity evaluation at the conclusion of the activity in order to receive a credit certificate.
In accordance with the disclosure policy of the Brown University CME Office as well as standards set forth by the Accreditation Council on Continuing Medical Education (ACCME), speakers have been asked to disclose any relevant financial relationship with the manufacturers of any commercial products and/or provider of commercial services discussed in any educational presentation and with any commercial supporters or exhibitors of this activity.
The intent of this policy is not to prevent a speaker with a potential conflict of interest from making a presentation but to identified openly so that the listener may form his/her own opinion. Any potential conflicts of interest have been resolved prior to this presentation.
This activity may include discussion of off-label or investigative drugs uses. Speakers are aware that it is their responsibility to disclose to the audience this information. Individual Faculty Disclosure information may be found in the conference handouts.
Faculty Disclosure/Conflict of Interest
The following planning committee members* have disclosed that they have no relevant financial relationships:
Eric Gartman, MD*
Douglas Martin, MD*
Barry Shea, MD^
Robert Simmons-Beck, MD
Maria Sullivan, BS*
Christopher Theroux, MD
^Speaker has indicated their presentation will include discussion of unlabeled/investigational use of a commercial product.
Disclaimer: This educational program is designed to present scientific information and opinion to Health professionals, to stimulate thought, and further investigation.
The Warren Alpert Medical School of Brown University is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians: The Warren Alpert Medical School of Brown University designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.
Other Healthcare Professionals: Participants will receive a Certificate of Attendance stating this program is designated for 1.0 hours AMA PRA Category 1 Credits™. This credit is accepted by the AAPA and AANP.
- 1.00 AMA PRA Category 1 Credit™The Warren Alpert Medical School of Brown University is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
- 1.00 AttendanceParticipants will receive a Certificate of Attendance stating this program is designated for AMA PRA Category 1 Credit™. This credit is accepted by the AAPA and AANP.